BioConst生物常量

Research reference only. BioConst updates and corrects content over time, but it cannot replace clinician-guided diagnosis, treatment, medication, or testing decisions.

Liver

Fatty liver disease and steatosis

Fat in the liver can reflect metabolic context and may require fibrosis-aware interpretation.

Clinician-guided interpretation page

This topic can involve test or imaging interpretation, neurological, cardiac, blood, liver, kidney, lung, surgical, medication, or complex underlying-disease context. BioConst keeps this page as an explainer, not a decision guide.

What this means

Fatty liver disease means fat is present in the liver and is interpreted with metabolic and fibrosis context.[1,2]

What people may notice

  • NAFLD is also referred to as MASLD in NIDDK patient material.[1,2]
  • Blood tests, imaging, and sometimes biopsy may enter diagnosis and staging context.[1,2]

Key variables

Hepatic steatosis

Fat in the liver is the structural starting point.[1,2]

Alanine aminotransferase (ALT)

ALT may be elevated, but enzymes alone do not determine severity.[1,2]

Liver fibrosis

Fibrosis context changes the meaning of fatty liver.[1,2]

Why it happens

  • Metabolic factors such as obesity, insulin resistance, diabetes, triglycerides, and metabolic syndrome can increase risk.[1,2]
  • Other causes of liver fat and alcohol-associated liver disease need clinical separation.[1,2]

Clinical response directions

  • Clinical teams may use history, exam, labs, imaging, and specialist review depending on fatty liver context.[1,2]
  • BioConst explains the map and does not diagnose, rank urgency, choose tests, or recommend treatment.[1,2]

Common traps

  • Fat on imaging does not automatically identify inflammation.[1,2]
  • Normal enzymes do not automatically exclude clinically important disease.[1,2]
  • Fatty liver is not a supplement target or a one-number problem.[1,2]

Related wiki variables